Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64


Antibody vs. HIV in a clash of evolutionary titans.

Burton DR, Stanfield RL, Wilson IA.

Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8. Epub 2005 Oct 11. Review.


GP120: target for neutralizing HIV-1 antibodies.

Pantophlet R, Burton DR.

Annu Rev Immunol. 2006;24:739-69. Review.


A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.

Kelker HC, Itri VR, Valentine FT.

PLoS One. 2010 Jan 5;5(1):e8555. doi: 10.1371/journal.pone.0008555.


The antigenic structure of the HIV gp120 envelope glycoprotein.

Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG.

Nature. 1998 Jun 18;393(6686):705-11.


Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.

Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R.

Virology. 2003 Sep 1;313(2):387-400.


Bioorganic approaches towards HIV vaccine design.

Wang LX.

Curr Pharm Des. 2003;9(22):1771-87. Review.


Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA.

Science. 2001 Aug 10;293(5532):1155-9.


Importance of conformation on the neutralizing antibody response to HIV-1 gp120.

Steimer KS, Haigwood NL.

Biotechnol Ther. 1991;2(1-2):63-89.


Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.

Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyƶ EM, Wahren B, Broliden K.

Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):461-5.


The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.

J Virol. 2001 Jun;75(12):5526-40.


Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.

Stamatos NM, Mascola JR, Kalyanaraman VS, Louder MK, Frampton LM, Birx DL, VanCott TC.

J Virol. 1998 Dec;72(12):9656-67.


Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 7.


Broadly neutralizing antibodies against HIV-1: templates for a vaccine.

van Gils MJ, Sanders RW.

Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004. Review.


Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

Grundner C, Li Y, Louder M, Mascola J, Yang X, Sodroski J, Wyatt R.

Virology. 2005 Jan 5;331(1):33-46.


Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein.

Thali M, Furman C, Wahren B, Posner M, Ho DD, Robinson J, Sodroski J.

J Acquir Immune Defic Syndr. 1992;5(6):591-9.


Supplemental Content

Support Center